Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 6/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | RXRG | P48443 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6079982 | 0.85 | MAPT (0.46) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL6081286 | 0.85 | CYP2C9 (0.46) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL6080263 | 0.84 | RXRA (0.45) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL6080525 | 0.82 | PTGER1 (0.46) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL6081119 | 0.82 | RNASEH1 (0.44) | MAPTTDP1L3MBTL1CYP2C19SMN1; SMN2 | |
| SCHEMBL6080351 | 0.80 | MAPT (0.49) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL6080121 | 0.80 | PTPN1 (0.41) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL6080513 | 0.79 | PTGER1 (0.50) | MAPTTDP1L3MBTL1CYP2C9CYP2C19 | |
| SCHEMBL6594874 | 0.77 | FOLH1 (0.47) | L3MBTL1PTGER1FOLH1CYP1A2POLB | |
| SCHEMBL6080809 | 0.76 | EPRS1 (0.36) | MAPTTDP1CYP2C9CYP2C19CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | claimed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | MAPT 1575/4885TDP1 2264/4885L3MBTL1 4069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.